ATE292472T1 - Verwendung von casb616 polypeptiden und polynukleotiden zur krebsbehandlung - Google Patents
Verwendung von casb616 polypeptiden und polynukleotiden zur krebsbehandlungInfo
- Publication number
- ATE292472T1 ATE292472T1 AT00907633T AT00907633T ATE292472T1 AT E292472 T1 ATE292472 T1 AT E292472T1 AT 00907633 T AT00907633 T AT 00907633T AT 00907633 T AT00907633 T AT 00907633T AT E292472 T1 ATE292472 T1 AT E292472T1
- Authority
- AT
- Austria
- Prior art keywords
- polynucleotides
- cancer treatment
- casb616
- polypeptides
- casb616 polypeptides
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 102000040430 polynucleotide Human genes 0.000 title abstract 2
- 108091033319 polynucleotide Proteins 0.000 title abstract 2
- 239000002157 polynucleotide Substances 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Catalysts (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9905124.5A GB9905124D0 (en) | 1999-03-05 | 1999-03-05 | Novel compounds |
| PCT/EP2000/001587 WO2000053216A2 (en) | 1999-03-05 | 2000-02-28 | Use of casb616 polypeptides and polynucleotides for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE292472T1 true ATE292472T1 (de) | 2005-04-15 |
Family
ID=10849064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00907633T ATE292472T1 (de) | 1999-03-05 | 2000-02-28 | Verwendung von casb616 polypeptiden und polynukleotiden zur krebsbehandlung |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20050129717A1 (de) |
| EP (2) | EP1162993B1 (de) |
| JP (1) | JP2002538218A (de) |
| KR (1) | KR20010102507A (de) |
| CN (1) | CN1374869A (de) |
| AT (1) | ATE292472T1 (de) |
| AU (1) | AU766789B2 (de) |
| BR (1) | BR0008784A (de) |
| CA (1) | CA2362370A1 (de) |
| CY (1) | CY1105585T1 (de) |
| CZ (1) | CZ20013189A3 (de) |
| DE (1) | DE60019273T2 (de) |
| ES (1) | ES2238026T3 (de) |
| GB (1) | GB9905124D0 (de) |
| HK (1) | HK1043729B (de) |
| HU (1) | HUP0200186A2 (de) |
| IL (1) | IL145046A0 (de) |
| NO (1) | NO20014292L (de) |
| NZ (1) | NZ513837A (de) |
| PL (1) | PL354143A1 (de) |
| PT (1) | PT1162993E (de) |
| TR (1) | TR200102577T2 (de) |
| WO (1) | WO2000053216A2 (de) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001271621A1 (en) * | 2000-06-28 | 2002-01-08 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
| DK2266603T3 (da) * | 2000-10-18 | 2012-11-05 | Glaxosmithkline Biolog Sa | Tumorvacciner |
| US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
| CN1446583A (zh) * | 2002-11-29 | 2003-10-08 | 帕弗瑞生物技术(北京)有限公司 | 一种肿瘤免疫治疗及预防性疫苗的组成、制备、应用方案 |
| CN107213469A (zh) | 2003-11-06 | 2017-09-29 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| CA2809819A1 (en) | 2009-09-09 | 2011-03-17 | Centrose, Llc | Extracellular targeted drug conjugates |
| WO2011130598A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| MX336540B (es) | 2010-06-08 | 2016-01-22 | Genentech Inc | Conjugados y anticuerpos manipulados geneticamente con cisteina. |
| ES2544608T3 (es) | 2010-11-17 | 2015-09-02 | Genentech, Inc. | Conjugados de anticuerpo y de alaninil-maitansinol |
| MX2013013054A (es) | 2011-05-12 | 2014-02-20 | Genentech Inc | Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura. |
| WO2013055987A1 (en) | 2011-10-14 | 2013-04-18 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
| WO2014057117A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| WO2014057120A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| HRP20181646T2 (hr) | 2012-10-12 | 2019-08-09 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin - anti-psma protutijela |
| KR101645905B1 (ko) | 2012-10-12 | 2016-08-04 | 스피로즌 살 | 피롤로벤조디아제핀 및 그의 컨주게이트 |
| PL2906251T3 (pl) | 2012-10-12 | 2018-02-28 | Adc Therapeutics Sa | Koniugaty pirolobenzodiazepina-przeciwciało anty-CD22 |
| MX364328B (es) | 2012-10-12 | 2019-04-23 | Medimmune Ltd | Conjugados del anticuerpo pirrolobenzodiazepina. |
| ES2680153T3 (es) | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas |
| CN105246894A (zh) | 2012-12-21 | 2016-01-13 | 斯皮罗根有限公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| AU2013366493B2 (en) | 2012-12-21 | 2017-08-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| EP2968585B1 (de) | 2013-03-13 | 2018-07-18 | Medimmune Limited | Pyrrolobenzodiazepine und konjugate davon |
| JP6445519B2 (ja) | 2013-03-13 | 2018-12-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びそのコンジュゲート |
| WO2014140862A2 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| US10442836B2 (en) | 2013-08-12 | 2019-10-15 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
| EP3054986B1 (de) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepin-antikörper-konjugate |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| BR112016013258A2 (pt) | 2013-12-16 | 2018-01-16 | Genentech Inc | composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit |
| JP6895254B2 (ja) | 2013-12-16 | 2021-06-30 | ジェネンテック， インコーポレイテッド | ペプチド模倣化合物及びその抗体−薬物コンジュゲート |
| CA2928952A1 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
| WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| US10077318B2 (en) | 2014-09-12 | 2018-09-18 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| US10149913B2 (en) | 2014-09-12 | 2018-12-11 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
| JP2017533887A (ja) | 2014-09-17 | 2017-11-16 | ジェネンテック， インコーポレイテッド | ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート |
| US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| CA2969689A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| NZ741261A (en) | 2015-10-02 | 2019-11-29 | Genentech Inc | Pyrrolobenzodiazepine antibody drug conjugates and methods of use |
| MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
| EP3365025B1 (de) | 2015-10-20 | 2020-07-15 | Genentech, Inc. | Calicheamicin-antikörper-arzneimittelkonjugate und verfahren zur verwendung |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| EP3433621A1 (de) | 2016-03-25 | 2019-01-30 | H. Hoffnabb-La Roche Ag | Multiplex-gesamtantikörper- und antikörper-konjugierter arzneimittelquantifizierungstest |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN118436801A (zh) | 2016-05-20 | 2024-08-06 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| US20170370906A1 (en) | 2016-05-27 | 2017-12-28 | Genentech, Inc. | Bioanalytical analysis of site-specific antibody drug conjugates |
| EP3464280B1 (de) | 2016-06-06 | 2021-10-06 | F. Hoffmann-La Roche AG | Silvestrol-antikörper-arzneimittelkonjugate und verfahren zur verwendung |
| WO2018031662A1 (en) | 2016-08-11 | 2018-02-15 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
| JP7050770B2 (ja) | 2016-10-05 | 2022-04-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| UA125198C2 (uk) | 2017-02-08 | 2022-01-26 | Ейдісі Терапьютікс Са | Кон'югати піролобензодіазепін-антитіло |
| SI3612537T1 (sl) | 2017-04-18 | 2022-10-28 | Medimmune Limited | Konjugati pirolobenzodiazepina |
| WO2018193102A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| JP7145891B2 (ja) | 2017-06-14 | 2022-10-03 | アーデーセー セラピューティクス ソシエテ アノニム | 抗ｃｄ１９ ａｄｃを投与するための投与レジメ |
| BR112020003003A2 (pt) | 2017-08-18 | 2020-08-11 | Medimmune Limited | conjugados de pirrolobenzodiazepina |
| AU2018337815A1 (en) | 2017-09-20 | 2020-03-12 | Ph Pharma Co., Ltd. | Thailanstatin analogs |
| US11068545B2 (en) | 2017-11-17 | 2021-07-20 | Battelle Memorial Institute | Spatial identification of assets using n-dimensional asset identifiers |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| WO2020086858A1 (en) | 2018-10-24 | 2020-04-30 | Genentech, Inc. | Conjugated chemical inducers of degradation and methods of use |
| EP3894427A1 (de) | 2018-12-10 | 2021-10-20 | Genentech, Inc. | Photovernetzende peptide zur stellenspezifischen konjugation an fc-haltige proteine |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| MX2021010477A (es) | 2019-03-15 | 2021-10-01 | Medimmune Ltd | Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer. |
| GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
| WO2022078524A2 (en) | 2021-11-03 | 2022-04-21 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| JP2026502860A (ja) | 2022-12-23 | 2026-01-27 | ジェネンテック， インコーポレイテッド | セレブロン分解剤コンジュゲートおよびその使用 |
| CN121263210A (zh) | 2023-04-17 | 2026-01-02 | 沛科生物公司 | 抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体 |
| WO2026006689A2 (en) | 2024-06-28 | 2026-01-02 | Firefly Bio, Inc. | Bcl-xl degrader antibody conjugates and uses thereof |
| WO2026006688A2 (en) | 2024-06-28 | 2026-01-02 | Firefly Bio, Inc. | Degrader antibody conjugates and uses thereof |
| CN120324603B (zh) * | 2025-04-28 | 2025-12-23 | 中奥生物医药技术(广东)有限公司 | 一种Caerin多肽联合树突状细胞疫苗在制备治疗乳腺癌药物中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000030673A1 (en) * | 1998-11-20 | 2000-06-02 | Genentech, Inc. | Uses for eph receptor antagonists and agonists to treat vascular disorders |
-
1999
- 1999-03-05 GB GBGB9905124.5A patent/GB9905124D0/en not_active Ceased
-
2000
- 2000-02-28 ES ES00907633T patent/ES2238026T3/es not_active Expired - Lifetime
- 2000-02-28 TR TR2001/02577T patent/TR200102577T2/xx unknown
- 2000-02-28 KR KR1020017011300A patent/KR20010102507A/ko not_active Ceased
- 2000-02-28 AT AT00907633T patent/ATE292472T1/de not_active IP Right Cessation
- 2000-02-28 JP JP2000603705A patent/JP2002538218A/ja active Pending
- 2000-02-28 EP EP00907633A patent/EP1162993B1/de not_active Expired - Lifetime
- 2000-02-28 IL IL14504600A patent/IL145046A0/xx unknown
- 2000-02-28 CZ CZ20013189A patent/CZ20013189A3/cs unknown
- 2000-02-28 EP EP04076929A patent/EP1466616A3/de not_active Withdrawn
- 2000-02-28 CA CA002362370A patent/CA2362370A1/en not_active Abandoned
- 2000-02-28 DE DE60019273T patent/DE60019273T2/de not_active Expired - Fee Related
- 2000-02-28 NZ NZ513837A patent/NZ513837A/xx unknown
- 2000-02-28 AU AU29153/00A patent/AU766789B2/en not_active Ceased
- 2000-02-28 BR BR0008784-0A patent/BR0008784A/pt not_active IP Right Cessation
- 2000-02-28 HU HU0200186A patent/HUP0200186A2/hu unknown
- 2000-02-28 PL PL00354143A patent/PL354143A1/xx not_active Application Discontinuation
- 2000-02-28 CN CN00807172A patent/CN1374869A/zh active Pending
- 2000-02-28 WO PCT/EP2000/001587 patent/WO2000053216A2/en not_active Ceased
- 2000-02-28 PT PT00907633T patent/PT1162993E/pt unknown
- 2000-02-28 HK HK02103796.8A patent/HK1043729B/en not_active IP Right Cessation
-
2001
- 2001-09-04 NO NO20014292A patent/NO20014292L/no not_active Application Discontinuation
-
2004
- 2004-11-09 US US10/984,521 patent/US20050129717A1/en not_active Abandoned
-
2005
- 2005-05-18 CY CY20051100614T patent/CY1105585T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2238026T3 (es) | 2005-08-16 |
| WO2000053216A2 (en) | 2000-09-14 |
| PT1162993E (pt) | 2005-06-30 |
| CZ20013189A3 (cs) | 2002-02-13 |
| HK1043729B (en) | 2005-11-04 |
| DE60019273T2 (de) | 2006-01-19 |
| WO2000053216A3 (en) | 2001-01-11 |
| IL145046A0 (en) | 2002-06-30 |
| TR200102577T2 (tr) | 2004-09-21 |
| AU766789B2 (en) | 2003-10-23 |
| AU2915300A (en) | 2000-09-28 |
| DE60019273D1 (de) | 2005-05-12 |
| NZ513837A (en) | 2003-02-28 |
| EP1162993B1 (de) | 2005-04-06 |
| EP1466616A2 (de) | 2004-10-13 |
| GB9905124D0 (en) | 1999-04-28 |
| EP1466616A3 (de) | 2004-12-01 |
| JP2002538218A (ja) | 2002-11-12 |
| CY1105585T1 (el) | 2010-07-28 |
| PL354143A1 (en) | 2003-12-29 |
| CN1374869A (zh) | 2002-10-16 |
| CA2362370A1 (en) | 2000-09-14 |
| NO20014292D0 (no) | 2001-09-04 |
| EP1162993A2 (de) | 2001-12-19 |
| US20050129717A1 (en) | 2005-06-16 |
| HUP0200186A2 (en) | 2002-05-29 |
| KR20010102507A (ko) | 2001-11-15 |
| BR0008784A (pt) | 2001-12-26 |
| HK1043729A1 (en) | 2002-09-27 |
| NO20014292L (no) | 2001-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE292472T1 (de) | Verwendung von casb616 polypeptiden und polynukleotiden zur krebsbehandlung | |
| EP2341148A3 (de) | Diagnose und behandlung von Krebs | |
| GB2317891C (en) | Human Telomerase Catalytic Subunit | |
| IL153052A0 (en) | Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods | |
| EP1543109A4 (de) | Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten | |
| HUP0300054A1 (hu) | Daganatspecifikus állati fehérjék | |
| DE602004020266D1 (de) | Therapeutische und diagnostische anti-hsp 70-antikörper | |
| DE60031383D1 (de) | Verwendung von casb618 polynucleotide und polypeptide | |
| DE60326931D1 (de) | In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren | |
| BR0009358A (pt) | Compostos | |
| WO2000043509A3 (en) | Polynucleotides and their applications in diagnostics | |
| WO2001023417A3 (en) | Human tumor-associated lak-4p related polynucleotides and polypeptides and their uses | |
| AU2003208871A8 (en) | Novel retina specific human proteins wdr17, net01, protein kinase a203, protein kinase mak a194, protein a105, protein a106 and c12orf3variants | |
| GB0120926D0 (en) | Proteins,genes and their use for diagnosis and treatment of breast cancer | |
| GB0110886D0 (en) | Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of erbB2-related cancer | |
| GB0128742D0 (en) | Nucleic acid molecules polypeptides and uses therefor including diagnosis and treatment of breast cancer | |
| GB0118385D0 (en) | Nucleic acid molecules polypeptides and uses therefor including diagnosis and treatment of breast cancer | |
| DE60226451D1 (de) | Menschliches protoonkogen kg-20 und darin codiertes protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1162993 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |